Future therapies for Behçet’s syndrome focus on **precision immunomodulation**:

biologics beyond TNF inhibitors (IL-1, IL-17, IL-23 blockers, interferon-α),

• • small molecules** like apremilast and JAK inhibitors,

targeting **NF-κB, neutrophil activation, and Th1/Th17 imbalance**, and **personalized approaches** using genetic and epigenetic markers to tailor treatment.

• Biologic Agents Beyond TNF Inhibitors

Interleukin Pathway Blockers

IL-1 inhibitors (anakinra, canakinumab, gevokizumab) → studied in refractory mucocutaneous and ocular disease.

IL-17 inhibitors (secukinumab) and IL-23 inhibitors → being explored for mucocutaneous and joint manifestations.

Interferon-α

Already used in ocular disease but continues to be evaluated as part of biologic strategies for refractory cases.

• Targeted Small-Molecule Therapies

Apremilast (PDE-4 inhibitor)

FDA-approved for oral ulcers in Behçet’s syndrome.

Represents the first oral targeted therapy in this condition.

Other small molecules targeting intracellular signaling pathways (e.g., JAK inhibitors) are under investigation, though not yet established in routine practice.

• Novel Immunomodulation Strategies

Ongoing research is evaluating precision immunomodulation to better target:

NF-κB signaling pathway (overactive in Behçet’s).

Innate immune overactivation (e.g., neutrophil hyperactivation, NET formation).

Adaptive T-cell imbalance (skewed Th1/Th17 vs. reduced T-reg activity).

• Personalized / Genomic Approaches

With advances in genomics and epigenetics, therapy may increasingly be guided by:

Genetic susceptibility loci (e.g., HLA-B*51, ERAP1, IL23R, TNFAIP3).

Epigenetic markers (aberrant DNA methylation, histone modifications).

These may help stratify patients for biologics vs. conventional immunosuppression.